Condition
Haemophilia A
Locations
Austria, Germany, Italy, Poland, Spain, United Kingdom, United States
Start date
23/10/2025
Identifiers
Trial ID NN7442-8454,
NCT number NCT07220564,
Eudract number 2025-520490-38
NCT number NCT07220564,
Eudract number 2025-520490-38
Summary
This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.
Trial Overview:
Treatment
DRUG: NNC0442-0344 A
Study type
INTERVENTIONAL
Trial duration
Oct 23 2025 - Dec 21 2026
Participants
30
Phase
I
Are you eligible?
Gender
MALE
Age
18 to 64 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.